Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-In-Class NMT Inhibitor, in Non-Hodgkin’s Lymphomas and Solid Tumor Patients

September 14, 2021 |

1 min read

PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage

Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
This open label, dose escalation study will examine the safety and tolerability of PCLX-001.